IPO Timeline
Broker Results (T-2)
2021-08-18
Some brokers release in afternoon
Grey Market (T-1)
2021-08-19
Afternoon
HKEX Allotment (T-1)
2021-08-19
Evening
Registrar Allotment (T-1)
2021-08-19
Evening
Listing Day (T)
2021-08-20
First day of trading
Company Overview
| Stock Name | 上海心瑋醫療科技股份有限公司 - B - H股 |
| Stock Code | 06609 |
| Company Full Name | 上海心瑋醫療科技股份有限公司 - B - H股 |
| Industry | 醫療保健 |
| Principal Activities | 主要於中國從事研發、制造及銷售神經介入及心臟醫療器械。 |
| Listing Date | 2021-08-20 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市張江高科技產業東區瑞慶路590號9幢南2層 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.heartcare.com.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism |
To be extracted
|
| Offer Price | HK$ 171.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 45.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 564,471,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 129.0 |
| First Day Open | HK$ 141.2 |
| First Day Change | -24.56% |
| First Day Volume | 2053800.0 |
| First Day Turnover | 281742000.0 |
Use of Proceeds
| Use of Proceeds | 1、約45.3%或約459.7百萬港元預期將分配至我們的核心產品;
2、約39.9%所或約404.9百萬港元預期將分配至我們管線內的其他在研產品;
3、約4.8%或約48.7百萬港元用于為透過內部研究提升研發能力及持續擴充產品組合提供資金;
4、約10.0%或約101.5百萬港元預期將用作營運資金及一般企業用途。 |
Underwriting Syndicate
Joint Sponsors (2)
高盛(亚洲)有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (2)
高盛(亚洲)有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (3)
高盛(亚洲)有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
富途证券国际(香港)有限公司 CE AZT137
Joint Lead Managers (3)
高盛(亚洲)有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
富途证券国际(香港)有限公司 CE AZT137
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
| 1 |
3W Funds |
23,324,400 HKD |
— |
2.07% |
— |
6 months |
2022-02-20 |
| 2 |
Aspex Master Fund |
77,745,150 HKD |
— |
6.89% |
— |
6 months |
2022-02-20 |
| 3 |
Boyu Capital Opportunities Master Fund |
77,745,150 HKD |
— |
6.89% |
— |
6 months |
2022-02-20 |
| 4 |
Goldstream Healthcare Focus Fund SP |
23,324,400 HKD |
— |
2.07% |
— |
6 months |
2022-02-20 |
| 5 |
Lake Bleu Prime Healthcare Master Fund Limited |
77,745,150 HKD |
— |
6.89% |
— |
6 months |
2022-02-20 |
| 6 |
LYFE CAPITAL FUND III (DRAGON), L.P. |
38,868,300 HKD |
— |
3.44% |
— |
6 months |
2022-02-20 |
| 7 |
Octagon Investments Master Fund LP |
77,745,150 HKD |
— |
6.89% |
— |
6 months |
2022-02-20 |
| 8 |
Sage Partners Master Fund |
38,868,300 HKD |
— |
3.44% |
— |
6 months |
2022-02-20 |
| 9 |
Superstring Capital Master Fund LP |
38,868,300 HKD |
— |
3.44% |
— |
6 months |
2022-02-20 |
| 10 |
The Valliance Fund |
38,868,300 HKD |
— |
3.44% |
— |
6 months |
2022-02-20 |
Directors & Management
| Chairman | 王國輝 |
| Company Secretary | 張涵,歐陽偉 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 王國輝(29.2%);LYFE Capital Management Limited(13.64%) |
Disclaimer & Risk Warning
Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.
Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.
Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.
Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.
Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.